Post I just made on IHUB:

New Post Public Reply Private Reply Replies (0) Message Board
petemantx
338
Post I just made on IHUB: Longs, time for a reality check:
IPIX positives include Brilacidin already a multi-billion dollar drug with excellent results in Ulcerative Colitis, Oral Mucocitis, and Antibiotic Phase 2's completed. Strong indications that it will work equally effective in the dermatology field for Acne, Eczema, and Hidratenitis Suppurativa. Remember, Dr Bertolino was VP Dermatology at Pfizer and Director of Dermatology at Novartis so he should be pretty capable of recognizing what will/will not work and he stands strong behind B for dermatology. Kevetrin also a multi-billion dollar drug since it showed everything BP was looking for in the recent Ovarian Cancer trial, that of good p53 being activated and mutant p53 being destroyed. IPIX has 20 or so CDA's signed with major pharmaceutical firms showing extreme interest in our entire pipeline.

Now we don't have deals signed yet, but they appear to be very close and these will solve the financial concerns of IPIX forever. Many may claim these are just pipe dreams, but look at the science, look at the results, look at the CDA's, and draw your own conclusion. If you can't see that IPIX already is to become a multi-billion dollar player in the next number of months than bail immediately. If you have the cognitive ability to add 2+2 and arrive at 4 then you will make the decision to sit tight and wait for the Prurisol P2b trial results and the following news on possible deals or the path Leo intends to take the company before you do anything rash with your shares.

IPIX doesn't need good Prurisol results to survive and be a multi billion dollar player, they already have that assurance from my comments above. Prurisol has shown itself to be extremely safe, far safer by quantum levels compared to anything else on the market today, it is already in pill form, and it showed in a 200 dose arm from a previous trial to be equal to or better than Otezla even though it appeared to only be entering its effective zone at a 200 dose level. This trial is at 300 and 400 and again, just add 2+2, who doesn't believe we will see vastly superior efficacy in the P2b compared to the P2a. Sure, many may put up a wall of BS to try and make the trial look real risky, but that is where you have to call them on their lies and distortion. Prurisol being effective against Psoriasis isn't a life or death situation for iPIX, but it will prove IMO to be an extremely profitable revenue stream as I have come to the conclusion, based on prior clinical results, that it will become first in class as to preferred treatment for Psoriasis.

The real crutch of the IPIX story are the deals upcoming and exactly how BP values our pipeline. That is another perfect storm for IPIX as many BPs have dwindling current pipelines, they have lots and lots of repatriated cash to buy new pipelines, and IPIX appears to have the strongest pipeline that has come down the pike at one time in maybe the history of medicine. I expect Leo is having more of a problem in choosing the perfect partner as opposed to finding the perfect partner.

Add it all up, remember it is as easy as 2+2, and see if the current hysteria which those that have bet against the company are trying to whip up by playing many trading games thru questionable MM practices are totally understandable as they see their financial destruction looming on the very near horizon.

Are 3 more weeks worth waiting and not getting upset over whether the SP sinks a bit more due to the trading games being played?

Easy as 2 + 2 = 4 use your head, not your emotions

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 7

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 5

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Security: The Fast Guard App Revolution

Updated Category News Views 109

Transforming Security with the Fast Guard App Fast Guard Service, a prominent name in licensed security guard services, has introduced a cutting-edge solution for the construction and property management sectors. This newly enhanced Fast Guard App empowers users to swiftly order and manage essential security services, including fire watch and armed or unarmed guards,...

Continue Reading
Weak Demand and Global Issues Impact China's Industries

Updated Category Economy Views 428

China's Industrial Profits Accelerate in June China's industrial gains in June increased more quickly, a reflection of good economic trends despite underlying problems. Official figures revealed a 3.6% year-on-year rise in profits, against a 0.7% increase in May. Strong industry output, according to the National Bureau of Statistics (NBS), helped to explain this increase....

Continue Reading
CyberArk Marks a Decade of Growth and Innovation Since IPO

Updated Category News Views 222

CyberArk Celebrates a Decade Since Its IPO In a significant milestone, CyberArk, a leader in identity security, marks ten years since its Initial Public Offering (IPO) on the NASDAQ. This anniversary serves as a moment for reflection and highlights essential achievements throughout the company's growth. Ringing the NASDAQ Bell to Honor Their Journey On the day of the...

Continue Reading
Projected Growth of the Biosurgery Market to $21.59 Billion

Updated Category News Views 145

Biosurgery Market Overview The global biosurgery market, currently valued at approximately US$14.96 billion, is expected to grow to a remarkable US$21.59 billion by a specified target year. This substantial growth, projected at an impressive CAGR of 6.4%, is fueled primarily by the urgent need for effective management of blood loss during surgical procedures and the rise...

Continue Reading
MIND Technology, Inc. Reports Growth Amidst Market Challenges

Updated Category News Views 188

Overview of MIND Technology's Recent Performance MIND Technology, Inc. (NASDAQ: MIND) has recently unveiled its financial outcomes for the third quarter of fiscal 2026. The company achieved revenues amounting to approximately $9.7 million during this period. Comparative Revenue Analysis This figure reflects a notable decrease from the $13.6 million realized in the prior...

Continue Reading